1. Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics. CA Cancer J Clin 2002; 52(1): 23-45.

2. Farhi D, Nosanchuk J, Silverberg S. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 1986; 68: 741-745.

3. Gallup D, Stock R. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984; 64: 417-420.

4. Brinton L, Hoover R. Epidemiology of gynecologic cancers. In: Principles and practice of gynecologic oncology (Hoskins W, Perez C, Young R, eds.), 3rd ed., Philadelphia: Lippincott, Williams and Wilkins, 2000, pp. 3-26.

5. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 1993; 81(2): 265-271.

6. Castellsague X, Thompson WD, Dubrow R. Intra-uterine contraception and the risk of endometrial cancer. Int J Cancer 1993; 54(6): 911-916.

7. Kvale G, Heuch I, Ursin G. Reproductive factors and risk of cancer of the uterine corpus: a prospective study. Cancer Res 1988; 48(21): 6217-6221.

8. Nyholm HC, Nielsen AL, Norup P. Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: comparison of clinical and histopathological characteristics. Gynecol Oncol 1993; 49(2): 229-235.

9. Schwartzbaum JA, Hulka BS, Fowler W Jr, Kaufman DG, Hoberman D. The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer. Am J Epidemiol 1987; 126(5): 851-860.

10. Horwitz R, Feinstein A, Horwitz S, Robboy S. Necropy diagnosis of endometrial cancer and detection-bias in case-control studies. Lancet 1981; 2: 66-68.

11. Fornander T, Cedarmark B, Mattson A. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 21: 117-119.

12. Fisher B, Constantino J, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B14. J Natl Cancer Inst 1994; 86: 527-531.

13. Magriples U, Naftolin F, Schwartz P, Carcangiu M. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11: 485-490.

14. Barakat R, Wong G, Curtin J, Vlamis V, Hoskins W. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence in adverse histologic features. Gynecol Oncol 1994; 55: 164-168.

15. Watson P, Vasen H, Mecklin J, Jarvinen H, Lynch H. The risk of endometrial cancer in hereditary nonpolyposius colorectal cancer. Am J Med 1994; 96: 516-520.

16. Bokhman J. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17.

17. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985; 56(6): p1452-p1455.

18. Deligdisch L, Holinka C. Progesterone receptors in two groups of endometrial carcinoma. Cancer 1986; 57: 1385-1388.

19. Silverberg S, Kurman R. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. Washington: Armed Forces Institute of Pathology; 1992, p27-p40.

20. Abeler V, Kjordstad K, Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer 1992; 2: 9-22.

21. Fanning J, Evans MC, Peters AJ, Samuel M, Harmon ER, Bates JS. Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile. Gynecol Oncol 1989; 32(3): 288-291.

22. Zaino R, Kurman R, Herbold D, et al. The significance of squamous differentiation in endometrial carcinoma. Cancer 1991; 68: 2293-2302.

23. Zaino RJ, Kurman RJ. Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma. Semin Diagn Pathol 1988; 5(2): 154-171.

24. Melhem MF, Tobon H. Mucinous adenocarcinoma of the endometrium: a clinico-pathological review of 18 cases. Int J Gynecol Pathol 1987; 6(4): 347-355.

25. Ross J, Eifel P, Cox R, Kempson R, Hendrickson M. Primary mucinous adenocarcinoma of the endometrium. Am J Surg Pathol 1983; 7: 715-729.

26. Tiltman A. Mucinous carcinoma of the endometrium. Obstet Gynecol 1980; 55: 244-247.

27. Abeler VM, Kjorstad KE. Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol 1990; 39(3): 266-271.

28. Ambros RA, Ballouk F, Malfetano JH, Ross JS. Significance of papillary (villoglandular) differentiation in endometrioid carcinoma of the uterus. Am J Surg Pathol 1994; 18(6): p569-p575.

29. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992; 47(3): 298-305.

30. Chen J, Trost D, Wilkinson E. Endometrial papillary adenocarcinomas: two clinicopathologic types. Int J Gynecol Pathol 1985; 4: 279-288.

31. Christopherson W, Alberhasky R, Connelly P. Carcinoma of the endometrium II. Papillary adenocar-cinoma: a clinicopathological study of 46 cases. Am J Clin Pathol 1982; 77: 534-540.

32. Gallion HH, van NJ Jr, Powell DF, et al. Stage I serous papillary carcinoma of the endometrium. Cancer 1989; 63(11): 2224-2228.

33. Hendrickson M, Martinez A, Ross J, Kempson R, Eifel P. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6: 93-108.

34. Lauchlan S. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 1981; 105: 615-618.

35. Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990; 3(2): 120-128.

36. Sutton GP, Brill L, Michael H, Stehman FB, Ehrlich CE. Malignant papillary lesions of the endometrium. Gynecol Oncol 1987; 27(3): 294-304.

37. Ward BG, Wright RG, Free K. Papillary carcinomas of the endometrium. Gynecol Oncol 1990; 39(3): 347-351.

38. Cirisano F, Robboy S, Dodge R, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999; 74(3): p385-p394.

39. Grice J, Ek M, Greer B, et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol 1998; 69(1): p69-p73.

40. Lee K, Belinson J. Papillary serous adenocarcinoma of the endometrium: a clinicopathologic study of 19 cases. Gynecol Oncol 1992; 46(1): p51-p54.

41. Mallipeddi P, Kapp D, Teng N. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma. Cancer 1993; 71(10): p3076-p3081.

42. Sakuragi N, Hareyama H, Todo Y, et al. Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma. Acta Obstet Gynecol Scand 2000; 79(4): p311-p316.

43. Sutton G, Brill L, Michael H, Stehman F, Ehrlich C. Malignant papillary lesions of the endometrium. Gynecol Oncol 1987; 27(3): p294-p304.

44. Abeler VM, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol 1991; 40(3): p207-p217.

45. Abeler VM, Vergote IB, Kjorstad KE, Trope CG. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 1996; 78(8): p1740-p1747.

46. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopatho-logic study of clear-cell carcinoma and secretory carcinoma. Cancer 1982; 49(8): p1511-p1523.

47. Lax SF, Pizer ES, Ronnett BM, Kurman RJ. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 1998; 29(6): p551-p558.

48. Webb GA, Lagios MD. Clear cell carcinoma of the endometrium. Am J Obstet Gynecol 1987; 156(6): p1486-p1491.

49. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991; 67(12): 3093-3103.

50. Cullen T. Cancer of the uterus: its pathology, symptomatology, diagnosis and treatment. New York: Appleton; 1900, p6-p30.

51. Eichhorn JH, Young RH, Clement PB. Sertoliform endometrial adenocarcinoma: a study of four cases. Int J Gynecol Pathol 1996; 15(2): p119-p126.

52. Beutler H, Dockerty M, Randall L. Precancerous lesions of the endometrium. Am J Obstet Gynecol 1963; 86: 433-443.

53. Campbell P, Barter R. The significance of atypical endometrial hyperplasia. J Obstet Gynaecol Br Commonw 1961; 68: 668-672.

54. Gusberg S, Al K. Precursors of corpus cancer:IV. adenomatous hyperplasia as stage 0 carcinoma of the endometrium. Am J Obstet Gynecol 1963; 87: 662-676.

55. Gore H, Hertig A. Carcinoma in situ of the endometrium. Am J Obstet Gynecol 1966; 94: 135-155.

56. Hendrickson M, Kempson R. Surgical pathology of the uterine corpus. Philadelphia: WB Saunders Co., 1980, 285-318.

57. Kurman R, Kaminski P, Norris H. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985; 56: 403-411.

58. Tavassoli F, Kraus F. Endometrial lesions in uteri resected for atypical endometrial hyperplasia. Am J Clin Pathol 1978; 70: 770-779.

59. Vellios F. Endometrial hyperplasia, precursors of endometrial carcinoma. Pathol Annu 1972; 7: 201-229.

60. Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol 1998; 22(8): p1012-p1019.

61. Skov BG, Broholm H, Engel U, et al. Comparison of the reproducibility of the WHO classifications of 1975 and 1994 of endometrial hyperplasia. Int J Gynecol Pathol 1997; 16(1): p33-p37.

62. Bergeron C, Nogales F, Masseroli M, et al. A multicentric European study testing the reproducibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 1999; 23: 1102-1108.

63. Colgan T, Norris H, Foster W, Kurman R, Fox C. Predicting the outcome of endometrial hyperplasia by quantitative analysis of nuclear features using a linear discriminant function. Int J Gynecol Pathol 1983; 1: 347-352.

64. Baak J. The use and disuse of morphometry in the diagnosis of endometrial hyperplasia and carcinoma. Path Res Pract 1984; 179: 20-23.

65. Baak JP. Further evaluation of the practical applicability of nuclear morphometry for the prediction of the outcome of atypical endometrial hyperplasia. Anal Quant Cytol Histol 1986; 8(1): p46-p48.

66. Baak JP, Nauta JJ, Wisse-Brekelmans EC, Bezemer PD. Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear mor-phometrical features alone. J Pathol 1988; 154(4): p335-p341.

67. Baak JP. The role of computerized morphometric and cytometric feature analysis in endometrial hyperplasia and cancer prognosis. J Cell Biochem Suppl 1995; 23: 137-146.

68. Ausems EW, van der Kamp JK, Baak JP. Nuclear morphometry in the determination of the prognosis of marked atypical endometrial hyperplasia. Int J Gynecol Pathol 1985; 4(3): p180-p185.

69. Baak JP, Wisse-Brekelmans EC, Fleege JC, van der Putten HW, Bezemer PD. Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. Pathol Res Pract 1992; 188(7): p856-p859.

70. Norris HJ, Becker RL, Mikel UV. A comparative morphometric and cytophotometric study of endometrial hyperplasia, atypical hyperplasia, and endometrial carcinoma. Hum Pathol 1989; 20(3): p219-p223.

71. Dunton CJ, Baak JP, Palazzo JP, van Diest PJ, McHugh M, Widra EA. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. Am J Obstet Gynecol 1996; 174(5): p1518-p1521.

72. Jovanovic A, Boynton K, Mutter G. Uteri of women with endometrial carcinoma conatina a histopathological spectrum of monoclonal putative precursors, some with microsatellite instability. Cancer Res 1996; 56: 1917-1921.

73. Mutter GL, Chaponot ML, Fletcher JA. A polymerase chain reaction assay for non-random X chromosome inactivation identifies monoclonal endometrial cancers and precancers. Am J Pathol 1995; 146(2): p501-p508.

74. Mutter G, Baak J, Crum C, Richart R, Ferenczy A, Faquin W. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000; 190: 462-469.

75. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000; 76(3): p287-p290.

76. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995; 26(11): p1260-p1267.

77. Sherman M. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; 13(3): p295-p308.

78. Sherman M, Bur M, Kurman R. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995; 26(11): p1268-p1274.

79. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992; 16(6): 600-610.

80. Spiegel G. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995; 19: 417-431.

81. Tashiro H, Isacson C, Levine R, Kurman R, Cho K, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997; 150(1): p177-p185.

82. Zheng W, Cao P, Zheng M, Kramer E, Godwin T. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996; 61(2): p167-p174.

83. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60(Suppl 8): 2035-2041.

84. Homesly H, Zaino R. Endometrial cancer: prognostic factors. Semin Oncol 1994; 21: 71-78.

85. Lampe B, Kurzl R, Hantschmann P. Reliability of tumor typing of endometrial carcinoma in prehys-terectomy curettage. Int J Gynecol Pathol 1995; 14: 2-6.

86. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40(1): 55-65.

87. Zaino RJ, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stageā€”a Gynecologic Oncology Group study. Cancer 1996; 77(6): p1115-p1121.

88. Zaino RJ. Conventional and novel prognostic factors in endometrial adenocarcinoma: a critical appraisal. Pathol Case Rev 2000; 5(3): 138-152.

89. Mariani A, Webb M, Keeney G, Aletti G, Podratz K. Assessment of prognostic factors in Stage IIIA endometrial cancer. Gynecol Oncol 2001; 86: 38-44.

90. Mariani A, Webb M, Keeney G, Lesnick T, Podratz K. Surgical Stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol 2002; 87: 274-280.

91. Daniel AG, Peters WD. Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol 1988; 71(4): 612-614.

92. Wheeler D, Bell K, Kurman R, Sherman M. Minimal uterine serous carcinoma: diagnostic and clini-copathologic correlation. Am J Surg Pathol 2000; 24: 797-806.

93. Aquino-Parsons C, Lim P, Wong F, Mildenberger M. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications. Gynecol Oncol 1998; 71(1): p83-p86.

94. Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol 1995; 14(1): p30-p38.

95. Kanbour-Shakir A, Tobon H. Primary clear cell carcinoma of the endometrium: a clinicopathologic study of 20 cases. Int J Gynecol Pathol 1991; 10(1): p67-p78.

96. Malpica A, Tornos C, Burke TW, Silva EG. Low-stage clear-cell carcinoma of the endometrium. Am J Surg Pathol 1995; 19(7): p769-p774.

97. Creasman WI. FIGO stages-1988 revision. Gynecol Oncol 1989; 35: 125-126.

98. Potish R, Twiggs L, Adcock L, al e. Paraaortic lymph node therapy in cancer of the uterine corpus. Obstet Gynecol 1985; 654: 251-157.

99. Aalders J, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 1984; 17: 85-92.

100. Kuten A, Grigsby P, Perez C, Fineberg B, Garcia D, Simpson J. Results of radiotherapy in recurrent endometrial carcinoma. Int J Radiat Oncol Biol Phys 1989; 17: 29-36.

101. Poulsen M, Roberts S. The salvage of recurrent endometrial carcinoma in the vagina and pelvis. Int J Radiat Oncol Biol Phys 1988; 15: 809-814.

102. Barakat R, Grigsby P, Sabatini P, Zaino R. Corpus: epithelial tumors. In: Principles and Practice of Gynecologic Oncology. (Hoskins W, Perez C, Young R, eds.), 3rd ed., Lippincott, William and Wilkins, Philadelphia, 2000, pp. 921-955.

103. Kistner R, Griffiths C, Craig J. Use of progestational agents in the management of endometrial cancer. Cancer 1965; 18: 1563-1579.

104. Montz F, Bristow R, Bovicelli A, Tomacruz R, Kurman R. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002; 186: 651-657.

105. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736-1744.

106. Mortel R, Zaino RJ, Satyaswaroop PG. Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model. Am J obstet Gynecol 1990; 162: 928-934.

107. Satyaswaroop PG, Clarke CL, Zaino RJ, Mortel R. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Cancer Lett 1992; 62: 107-114.

108. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 4-9.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment